We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Brazilian drug pricing authority CMED's ongoing "freeze" on drug prices -- which is set to expire only in March 2006 -- remains a cause for concern for many foreign drug firms.
French drugmakers' association LEEM and pricing regulator CEPS have agreed to limit visits to doctors from representatives of pharmaceutical companies.
The international drug industry has continued to criticise patent protection in Indonesia. Recent developments have been mixed, with the authorities implementing some of the terms of TRIPS by the end of 2004, despite pledges to introduce the treaty by 2000.
Alcon, Inc. (NYSE:ACL) reported global sales of $1,172.0 million for the second quarter of 2005, an increase of 12.8 percent over global sales in the second quarter of 2004, or 10.1 percent excluding the impact of foreign exchange fluctuations.
BG Medicine announced today that it has entered into an agreement with Boehringer Ingelheim Pharmaceuticals, Inc. BG Medicine will apply its Systems Pharmacology platform to elucidate tissue drug effects and discover circulating biomarkers for clinical application.
GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) and Scancell Limited ("Scancell") announced that they have signed a collaboration agreement to evaluate the expression of Scancell's SC101 anti-cancer monoclonal antibody (MAb) using GTC's transgenic production platform.
Wyeth Japan announced on July 25 that it has obtained approval for Mylotarg, a proprietary preparation of gemtuzumab ozogamicin, from the Ministry of Health, Labor and Welfare.
Antibody therapeutic company EvoGenix has closed its $9 million initial public offer early following strong support from institutional and retail investors.